
Sign up to save your podcasts
Or


Maybe CAR T-cell therapy is the treatment of choice for your patient with triple-class refractory multiple myeloma? Join the discussion now!
Credit available for this activity expires: 3/23/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/970643?src=mkm_podcast_addon_970643
By Medscape Podcasts4
77 ratings
Maybe CAR T-cell therapy is the treatment of choice for your patient with triple-class refractory multiple myeloma? Join the discussion now!
Credit available for this activity expires: 3/23/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/970643?src=mkm_podcast_addon_970643

320 Listeners

497 Listeners

1,639 Listeners

881 Listeners

14 Listeners

16 Listeners

292 Listeners

3,348 Listeners

8,522 Listeners

193 Listeners

93 Listeners

513 Listeners

369 Listeners

61 Listeners

28 Listeners

425 Listeners

374 Listeners

29,188 Listeners

65 Listeners